



(11) **EP 3 311 666 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A01N 35/00 ^(2006.01) **A61K 31/12** ^(2006.01)
C07D 319/18 ^(2006.01) **C07D 405/06** ^(2006.01)
C07D 405/10 ^(2006.01) **C07D 407/10** ^(2006.01)
C07D 409/06 ^(2006.01) **C07D 409/10** ^(2006.01)
C07C 49/784 ^(2006.01) **C07D 213/50** ^(2006.01)
A61P 25/00 ^(2006.01)

(48) Corrigendum issued on:
23.06.2021 Bulletin 2021/25

(45) Date of publication and mention
of the grant of the patent:
05.05.2021 Bulletin 2021/18

(21) Application number: **17193280.9**

(22) Date of filing: **17.08.2011**

(54) **DIKETONES AND HYDROXYKETONES AS CATENIN SIGNALING PATHWAY ACTIVATORS**

DIKETONE UND HYDROXYKETONE ALS CATENINSIGNALWEG-AKTIVATOREN

DICÉTONES ET HYDROXYDICÉTONES UTILES EN TANT QU'ACTIVATEURS DE LA VOIE DE
SIGNALISATION DE LA CATÉNINE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **18.08.2010 US 374687 P**
29.12.2010 US 201061427974 P

(43) Date of publication of application:
25.04.2018 Bulletin 2018/17

(60) Divisional application:
21167222.5

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
11818727.7 / 2 605 652

(73) Proprietor: **BioSplice Therapeutics, Inc.**
San Diego, CA 92121 (US)

(72) Inventors:
• **KC, Sunil Kumar**
San Diego, CA 92127 (US)
• **WALLACE, David Mark**
San Diego, CA 92121 (US)
• **HOOD, John**
San Diego, CA 92130 (US)
• **BARROGA, Charlene F.**
San Diego, CA 92122 (US)

(74) Representative: **D Young & Co LLP**
120 Holborn
London EC1N 2DY (GB)

(56) References cited:
WO-A1-2010/075551

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).